# Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Mepolizumab (SASAM Study)

> **NCT05040997** · — · UNKNOWN · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 40 (estimated)

## Conditions studied

- Small Airway Disease
- Asthma

## Interventions

- **DIAGNOSTIC_TEST:** Small airways assessment

## Key facts

- **NCT ID:** NCT05040997
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-05-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040997, "Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Mepolizumab (SASAM Study)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05040997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*